Several analysts have recently updated their ratings and price targets for Prelude Therapeutics (NASDAQ: PRLD):
- 7/29/2026 – Prelude Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 7/29/2026 – Prelude Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $8.00 price target on the stock.
- 7/25/2026 – Prelude Therapeutics was upgraded by Wall Street Zen from “hold” to “buy”.
- 7/15/2026 – Prelude Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.
Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.
Featured Stories
- Five stocks we like better than Prelude Therapeutics
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Prelude Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.
